Core Insights - Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for oncology and other diseases [1][3] - The company will present at the Guggenheim Securities SMID Cap Biotech Conference in New York City on February 5-6, 2025 [1][2] Company Overview - Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics specializes in the relationship between angiogenesis, the immune system, and tumor growth [3] - The company's pipeline includes novel product candidates targeting critical biological pathways for effective anti-tumor responses, including angiogenesis modulation and immune response induction [3] - Compass plans to advance its product candidates through clinical development as standalone therapies and in combination with proprietary pipeline antibodies [3]
Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference